8月19日，施贵宝盘中上涨3.11%，报68.1美元/股，成交额1.1亿美元。
消息面上，FDA于8月14日授予施贵宝首款Celmod疗法Zenbexus联合达雷妥尤单抗及地塞米松的加速批准，用于治疗至少接受过一线治疗的多发性骨髓瘤成人患者。三期临床数据显示，Zenbexus组合方案的微小残留病灶阴性完全缓解率达41%，显著优于对照组的21%。此外，公司近期宣布斥资23亿美元在休斯敦建设新制造园区，进一步强化美国本土产能布局。当日制药板块整体表现强劲，默沙东涨10.37%、礼来涨4.61%、辉瑞涨3.23%，板块联动效应亦对施贵宝形成提振。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.